Galapagos is a company specializing in novel mechanisms of small-molecule and antibody programs for cystic fibrosis. In a recent press release, the company revealed that before the end of 2015, they are going to conduct a Phase 1 clinical trial of a new corrector called GLPG2222 in conjunction…
Specialty biopharmaceutical company Shire has just announced a new partnership with the Cystic Fibrosis Foundation to develop technology that can maintain and/or restore lung function, as well as protect against respiratory infections — two primary health concerns in people living with cystic fibrosis (CF). The announcement was made…
A new study from a team of researchers of the University of Pittsburgh Center for Vaccine Research (CVR), entitled “Engineered Cationic Antimicrobial Peptides (eCAPs) to Overcome Multidrug Resistance by ESKAPE Pathogens” demonstrated the effectiveness of new antibiotic agents as inhibitors of the growth of drug-resistant bacteria. The findings…
The Mauli Ola Foundation’s (MOF) 2014 national Ohana Tour will finish on the North Shore of Oahu, and the event will include pediatric visits and Surf Experience Days to help those suffering with cystic fibrosis. Jamie O’Brien, the pipeline master, will be hosting the final 2014 Surf Experience which…
One of the ways the Cystic Fibrosis Trust is celebrating its 50th Anniversary this year is through a month-long Thank You campaign, meant to cap off the year on a high note, and with a surge of hope. The UK not-for-profit organization created a…
Thanks to a fundraising initiative organized by the staff members of the University Hospital of South Manchester NHS Foundation Trust (UHSM), patients at the facility who suffer from cystic fibrosis (CF) now have the possibility of improving their symptoms using state-of-the-art exercise equipment, with two new, modern exercise bikes…
A new Cystic Fibrosis study entitled “Early Respiratory Infection Is Associated with Reduced Spirometry in Children with Cystic Fibrosis” was published in American Journal of Respiratory and Critical Care Medicine by Dr. Kathryn A. Ramsey, part of Graham L. Hall’s group from the Telethon Kids…
Drug developer Proteostasis Therapeutics, Inc., which is currently studying protein homeostasis regulation as a treatment for orphan and neurodegenerative diseases such as cystic fibrosis (CF), recently named Po-Shun Lee, MD as their new vice-president of clinical development. The pulmonary and critical care physician, who has been responsible for leading research programs on…
Virginia-based surgical and medical instrument manufacturer PulmoFlow, Inc. announced Tuesday, December 2 that the US Food and Drug Administration has granted final approval of its New Drug Application for the Kitabis Pak. The drug is a co-packaging of tobramycin inhalation solution and the PARI LC PLUS® Reusable Nebulizer, which is the first…
A new study published in the Orphanet Journal of Rare Diseases, presented the effectiveness of Cysteamine for the treatment of Cystic Fibrosis. The study, entitled “Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis” was conducted by NovaBiotics Ltd. researchers. Cystic…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.